Growing Revenue Stream Tenon Medical has achieved a significant revenue increase to an estimated $10 million to $25 million, driven by record sales of its innovative sacro-pelvic fusion systems. This growth indicates strong market acceptance and potential for expanding sales territories and product lines.

Innovative Product Portfolio The launch of FDA-cleared SImmetry+ SI Joint Fusion System and the continued development of minimally invasive fusion technologies position Tenon as a leader in the sacro-pelvic market, creating opportunities to upsell or cross-sell to healthcare providers seeking advanced treatment options.

Expanding Clinical Evidence Recent peer-reviewed publications and ongoing clinical trials demonstrating positive patient outcomes and fusion success rates can be leveraged to build trust and accelerate adoption among surgeons and hospitals, opening sales channels in academic and high-volume surgical centers.

Funding for Growth With successful PIPE financing raising nearly $2.85 million, Tenon has the financial resources to support broad product distribution, marketing campaigns, and strategic partnerships—creating opportunities for sales teams to target new and existing healthcare facilities.

Market Expansion Potential Given the company’s focus on sacro-pelvic disorders and serious health conditions like sacroiliac joint disruptions and degenerative sacroiliitis, there is a substantial opportunity to engage specialty clinics, orthopedic and spine surgeons, and hospitals looking for proven minimally invasive solutions to grow their surgical offerings.